$DYN
Dyne Therapeutics Inc

2022 Q4 Form 10-Q Financial Statement

#000095017022021546 Filed on November 03, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.955M $7.609M $6.256M
YoY Change -27.99% 21.63% 62.92%
% of Gross Profit
Research & Development $33.19M $34.67M $36.51M
YoY Change -21.54% -5.04% 277.21%
% of Gross Profit
Depreciation & Amortization $401.0K $400.0K $300.0K
YoY Change 17.6% 33.33% 50.0%
% of Gross Profit
Operating Expenses $40.15M $42.28M $42.77M
YoY Change -22.74% -1.14% 216.32%
Operating Profit -$42.28M -$42.77M
YoY Change -1.14% 216.32%
Interest Expense $1.342M $903.0K $184.0K
YoY Change 637.36% 390.76% -241.54%
% of Operating Profit
Other Income/Expense, Net -$24.00K $894.0K $184.0K
YoY Change 200.0% 385.87% -146.0%
Pretax Income -$38.83M -$41.39M -$42.58M
YoY Change -25.02% -2.81% 205.91%
Income Tax
% Of Pretax Income
Net Earnings -$38.83M -$41.39M -$42.58M
YoY Change -25.02% -2.81% 205.91%
Net Earnings / Revenue
Basic Earnings Per Share -$0.80 -$0.83
Diluted Earnings Per Share -$0.74 -$0.80 -$829.7K
COMMON SHARES
Basic Shares Outstanding 52.13M 51.77M
Diluted Shares Outstanding

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $256.0M $248.1M $407.5M
YoY Change -32.01% -39.11% 7.36%
Cash & Equivalents $172.1M $144.9M $229.0M
Short-Term Investments $83.87M $103.2M $178.5M
Other Short-Term Assets $9.582M $10.09M $17.13M
YoY Change 64.61% -41.09% 8466.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $265.6M $258.2M $424.7M
YoY Change -30.54% -39.19% 11.8%
LONG-TERM ASSETS
Property, Plant & Equipment $5.945M $5.742M $2.988M
YoY Change 27.08% 92.17% 107.36%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.319M $2.317M $2.308M
YoY Change 0.35% 0.39% 1108.38%
Total Long-Term Assets $40.73M $41.45M $42.22M
YoY Change -5.87% -1.84% 2487.19%
TOTAL ASSETS
Total Short-Term Assets $265.6M $258.2M $424.7M
Total Long-Term Assets $40.73M $41.45M $42.22M
Total Assets $306.3M $299.7M $466.9M
YoY Change -28.04% -35.81% 22.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.259M $919.0K $7.088M
YoY Change 30.46% -87.03% 376.34%
Accrued Expenses $22.83M $22.40M $16.26M
YoY Change -7.54% 37.75% 502.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $28.09M $23.32M $23.35M
YoY Change -2.21% -0.13% 399.17%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $25.87M $26.61M $29.41M
YoY Change -9.99% -9.51%
Total Long-Term Liabilities $25.87M $26.61M $29.41M
YoY Change -9.99% -9.51% 196.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $28.09M $23.32M $23.35M
Total Long-Term Liabilities $25.87M $26.61M $29.41M
Total Liabilities $53.96M $49.94M $52.76M
YoY Change -6.1% -5.36% 261.04%
SHAREHOLDERS EQUITY
Retained Earnings -$396.6M -$357.7M -$176.7M
YoY Change 73.57% 102.47% 249.64%
Common Stock $6.000K $6.000K $6.000K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $252.4M $249.7M $414.1M
YoY Change
Total Liabilities & Shareholders Equity $306.3M $299.7M $466.9M
YoY Change -28.04% -35.81% 22.39%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$38.83M -$41.39M -$42.58M
YoY Change -25.02% -2.81% 205.91%
Depreciation, Depletion And Amortization $401.0K $400.0K $300.0K
YoY Change 17.6% 33.33% 50.0%
Cash From Operating Activities -$29.19M -$42.81M -$26.95M
YoY Change 4.0% 58.82% 127.06%
INVESTING ACTIVITIES
Capital Expenditures $519.0K -$886.0K -$881.0K
YoY Change -126.08% 0.57% 450.63%
Acquisitions
YoY Change
Other Investing Activities $19.76M $52.54M -$1.967M
YoY Change 1025.7% -2771.28%
Cash From Investing Activities $19.24M $51.66M -$2.848M
YoY Change -8285.96% -1913.83% 1680.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 37.20M 70.00K 457.0K
YoY Change 41701.12% -84.68% -99.88%
NET CHANGE
Cash From Operating Activities -29.19M -42.81M -26.95M
Cash From Investing Activities 19.24M 51.66M -2.848M
Cash From Financing Activities 37.20M 70.00K 457.0K
Net Change In Cash 27.25M 8.923M -29.34M
YoY Change -196.58% -130.41% -107.98%
FREE CASH FLOW
Cash From Operating Activities -$29.19M -$42.81M -$26.95M
Capital Expenditures $519.0K -$886.0K -$881.0K
Free Cash Flow -$29.71M -$41.92M -$26.07M
YoY Change 13.93% 60.79% 122.64%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Central Index Key
EntityCentralIndexKey
0001818794
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39509
dei Entity Registrant Name
EntityRegistrantName
Dyne Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
36-4883909
dei Entity Address Address Line1
EntityAddressAddressLine1
1560 Trapelo Road
dei Entity Address City Or Town
EntityAddressCityOrTown
Waltham
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02451
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
786-8230
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
DYN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
52126892
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
144901000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
200825000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
103241000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
175746000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10092000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5821000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
258234000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
382392000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5742000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4678000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
33386000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
36282000
CY2022Q3 dyn Restricted Cash And Other Assets Noncurrent
RestrictedCashAndOtherAssetsNoncurrent
2317000
CY2021Q4 dyn Restricted Cash And Other Assets Noncurrent
RestrictedCashAndOtherAssetsNoncurrent
2311000
CY2022Q3 us-gaap Assets
Assets
299679000
CY2021Q4 us-gaap Assets
Assets
425663000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
919000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4031000
CY2022Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
17826000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
20799000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4576000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3893000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
23321000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
28723000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
26614000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
28743000
CY2022Q3 us-gaap Liabilities
Liabilities
49935000
CY2021Q4 us-gaap Liabilities
Liabilities
57466000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
51909235
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
51607522
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
51906773
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
51569381
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0411
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
6000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
6000
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
608467000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
596934000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-983000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-269000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-357746000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-228474000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
249744000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
368197000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
299679000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
425663000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
34670000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
36510000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
109570000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
79007000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7609000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6256000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21247000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19058000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
42279000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
42766000
us-gaap Operating Expenses
OperatingExpenses
130817000
us-gaap Operating Expenses
OperatingExpenses
98065000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-42279000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-42766000
us-gaap Operating Income Loss
OperatingIncomeLoss
-130817000
us-gaap Operating Income Loss
OperatingIncomeLoss
-98065000
CY2022Q3 us-gaap Interest Income Other
InterestIncomeOther
903000
CY2021Q3 us-gaap Interest Income Other
InterestIncomeOther
184000
us-gaap Interest Income Other
InterestIncomeOther
1575000
us-gaap Interest Income Other
InterestIncomeOther
560000
CY2022Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-9000
CY2021Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
0
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-30000
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
0
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
894000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
184000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1545000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
560000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-41385000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-42582000
us-gaap Net Income Loss
NetIncomeLoss
-129272000
us-gaap Net Income Loss
NetIncomeLoss
-97505000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.80
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.80
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.83
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.83
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.50
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.50
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.92
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.92
CY2022Q3 us-gaap Weighted Average Limited Partnership Units Outstanding Diluted
WeightedAverageLimitedPartnershipUnitsOutstandingDiluted
51795446
CY2022Q3 us-gaap Weighted Average Limited Partnership Units Outstanding
WeightedAverageLimitedPartnershipUnitsOutstanding
51795446
CY2021Q3 us-gaap Weighted Average Limited Partnership Units Outstanding Diluted
WeightedAverageLimitedPartnershipUnitsOutstandingDiluted
51320940
CY2021Q3 us-gaap Weighted Average Limited Partnership Units Outstanding
WeightedAverageLimitedPartnershipUnitsOutstanding
51320940
us-gaap Weighted Average Limited Partnership Units Outstanding Diluted
WeightedAverageLimitedPartnershipUnitsOutstandingDiluted
51692899
us-gaap Weighted Average Limited Partnership Units Outstanding
WeightedAverageLimitedPartnershipUnitsOutstanding
51692899
us-gaap Weighted Average Limited Partnership Units Outstanding Diluted
WeightedAverageLimitedPartnershipUnitsOutstandingDiluted
50676668
us-gaap Weighted Average Limited Partnership Units Outstanding
WeightedAverageLimitedPartnershipUnitsOutstanding
50676668
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-41385000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-42582000
us-gaap Net Income Loss
NetIncomeLoss
-129272000
us-gaap Net Income Loss
NetIncomeLoss
-97505000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
173000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
7000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-714000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-7000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-41212000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-42575000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-129986000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-97512000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
368197000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
18000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4488000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-661000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-35583000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
336459000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
99000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3031000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-226000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-52304000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
287059000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
70000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3827000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
173000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-41385000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
249744000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
342367000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0082
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
157237000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
13000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3652000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-41000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-24968000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
478260000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
25000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4239000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
27000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-29955000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
452596000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
457000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3638000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
7000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-42582000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
414116000
us-gaap Profit Loss
ProfitLoss
-129272000
us-gaap Profit Loss
ProfitLoss
-97505000
us-gaap Share Based Compensation
ShareBasedCompensation
11346000
us-gaap Share Based Compensation
ShareBasedCompensation
11529000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1282000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
747000
dyn Non Cash Lease Expense
NonCashLeaseExpense
1448000
dyn Non Cash Lease Expense
NonCashLeaseExpense
-28000
dyn Amortization Accretion Of Premium Discount On Marketable Securities
AmortizationAccretionOfPremiumDiscountOnMarketableSecurities
1248000
dyn Amortization Accretion Of Premium Discount On Marketable Securities
AmortizationAccretionOfPremiumDiscountOnMarketableSecurities
1843000
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-30000
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4654000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
12816000
dyn Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
0
dyn Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
2940000
us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
-5881000
us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
7675000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-124453000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-91495000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2548000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1628000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
94712000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
208207000
dyn Maturities Of Marketable Securities
MaturitiesOfMarketableSecurities
162466000
dyn Maturities Of Marketable Securities
MaturitiesOfMarketableSecurities
72178000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
2759000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
67965000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-137657000
dyn Proceeds From Issuance Follow On Public Offering
ProceedsFromIssuanceFollowOnPublicOffering
0
dyn Proceeds From Issuance Follow On Public Offering
ProceedsFromIssuanceFollowOnPublicOffering
157237000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
187000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
495000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
187000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
157732000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-56301000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-71420000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
203519000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
303153000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
147218000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
231733000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
161000
dyn Right Of Use Assets Acquired Under Operating Leases
RightOfUseAssetsAcquiredUnderOperatingLeases
0
dyn Right Of Use Assets Acquired Under Operating Leases
RightOfUseAssetsAcquiredUnderOperatingLeases
33799000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2017-12-01
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0117
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7967750
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.35
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M12D
us-gaap Dividends Common Stock
DividendsCommonStock
9292981000
us-gaap Dividends Common Stock
DividendsCommonStock
8008689000
dyn Cash And Cash Equivalents Maturity Period
CashAndCashEquivalentsMaturityPeriod
P90D
CY2022Q3 us-gaap Restricted Cash
RestrictedCash
2300000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
2700000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
144901000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
200825000
CY2022Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
0
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
383000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2317000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2311000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
147218000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
203519000
CY2022Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
104224000
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
983000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
103241000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
176015000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
272000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
175746000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
36946000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
845469
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.24
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
61304
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
101022000
CY2022Q3 dyn Available For Sale Debt Securities Maturing In One Year Through Two Years
AvailableForSaleDebtSecuritiesMaturingInOneYearThroughTwoYears
2219000
CY2022Q3 dyn Available For Sale Debt Securities Maturity After Year Two Years Fair Value
AvailableForSaleDebtSecuritiesMaturityAfterYearTwoYearsFairValue
0
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
103241000
CY2022Q3 dyn Fair Value Assets Transfers Amount
FairValueAssetsTransfersAmount
0
CY2021Q4 dyn Fair Value Assets Transfers Amount
FairValueAssetsTransfersAmount
0
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9007000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6661000
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3265000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1983000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5742000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4678000
CY2022Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
400000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1300000
CY2021Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
300000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
700000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.07
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
399084
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
12.15
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8352831
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.15
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M6D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
42542000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3855012
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.95
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y9M18D
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4428000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5097000
CY2022Q3 dyn Accrued Consulting Services Current
AccruedConsultingServicesCurrent
904000
CY2021Q4 dyn Accrued Consulting Services Current
AccruedConsultingServicesCurrent
694000
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
454000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
184000
CY2022Q3 dyn Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
12040000
CY2021Q4 dyn Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
14762000
CY2022Q3 dyn Accrued Facility Costs Current
AccruedFacilityCostsCurrent
0
CY2021Q4 dyn Accrued Facility Costs Current
AccruedFacilityCostsCurrent
62000
CY2022Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
17826000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
20799000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.71
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.74
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0147
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
24240000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
8352831
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
9.15
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y1M6D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
42542000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
400000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1600000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.33
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
11.68
dyn Vesting Stock Options
VestingStockOptions
582441
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
188950
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.97
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
240409
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
18.58
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
67837
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
16.68
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
14.99
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y10M24D
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3827000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3638000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11346000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11529000

Files In Submission

Name View Source Status
0000950170-22-021546-index-headers.html Edgar Link pending
0000950170-22-021546-index.html Edgar Link pending
0000950170-22-021546.txt Edgar Link pending
0000950170-22-021546-xbrl.zip Edgar Link pending
dyn-20220930.htm Edgar Link pending
dyn-20220930.xsd Edgar Link pending
dyn-ex10_1.htm Edgar Link pending
dyn-ex31_1.htm Edgar Link pending
dyn-ex31_2.htm Edgar Link pending
dyn-ex32_1.htm Edgar Link pending
dyn-20220930_cal.xml Edgar Link unprocessable
dyn-20220930_def.xml Edgar Link unprocessable
dyn-20220930_pre.xml Edgar Link unprocessable
dyn-20220930_lab.xml Edgar Link unprocessable
dyn-20220930_htm.xml Edgar Link completed
dyn-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable